The biology behind bone that rebuilds itself
OssiGel works in two directions from the same core technology. It regenerates bone inside the body, and it models bone marrow outside it. Both start with the same engineered human cartilage matrix.
Application one
Regenerating bone through endochondral ossification
OssiGel does not deliver bone. It delivers the signal that tells the body to build its own. The material recruits the patient's own progenitor cells rather than relying on implanted living cells, and it presents the natural cartilage extracellular matrix, over 2,000 proteins including VEGF and BMP-2, instead of a single supraphysiologic growth factor. That signaling environment promotes vascularization and progressive remodeling into mature bone, mirroring the same pathway the body already uses after a fracture.
The material is cell-free and DNA-depleted, with decellularization efficiency above 99.7% and residual DNA below the field's recommended safety threshold. In human allogeneic assays it triggered minimal T-cell activation and reduced dendritic cell maturation, consistent with an off-the-shelf product that does not require donor matching.
OssiGel does not deliver bone. It delivers the signal that tells the body to build its own. The material recruits the patient's own progenitor cells rather than relying on implanted living cells, and it presents the natural cartilage extracellular matrix, over 2,000 proteins including VEGF and BMP-2, instead of a single supraphysiologic growth factor. That signaling environment promotes vascularization and progressive remodeling into mature bone, mirroring the same pathway the body already uses after a fracture.
The material is cell-free and DNA-depleted, with decellularization efficiency above 99.7% and residual DNA below the field's recommended safety threshold. In human allogeneic assays it triggered minimal T-cell activation and reduced dendritic cell maturation, consistent with an off-the-shelf product that does not require donor matching.
Application two
Modeling bone marrow with the patient's own cells
The same engineered matrix that regenerates bone in the body can also build a bone marrow niche outside it. Patient tumor and stromal cells are isolated, mixed with OssiGel, and injected to form a humanized ossicle, hOss, a miniature, patient-specific bone marrow environment that recreates the composition of the original niche.
In acute myeloid leukemia samples, autologous hOss reached a 93% ossicle formation success rate across 269 patient-derived ossicles generated to date, and that success rate held regardless of the patient's ELN risk classification. Once formed, AML cells that circulate through the mouse system preferentially localize in the hOss, giving researchers a standardized platform for disease modeling with composition similarities to the patient's original bone marrow, with reproducibility above 95% and 75% fewer animals required than conventional models.
